Comparing the current results to its competitors, Exscientia Plc reported Revenue increase in the 4 quarter 2021 by 0 % year on year. The revenue growth was below Exscientia Plc's competitors' average revenue growth of 31.07 %, achieved in the same quarter.
Exscientia Plc's Comment on Competition and Industry Peers
The company is developing multiple drug programs, including a lead CDK7 inhibitor (GTAEXS617) currently in Phase 1/2 trials and a PKC-theta inhibitor designed for Bristol Myers Squibb, which is in Phase 1 trials. The PKC-theta inhibitor aims to achieve potency and selectivity not attained by previous candidates. Additionally, the company has internal programs targeting LSD1 and MALT1 to address toxicities observed in competing programs. The company operates in a competitive and rapidly evolving AI drug discovery and design market, facing competition from pharmaceutical companies, biotechnology firms, academic institutions, governmental agencies, consortiums, and research institutions of varying sizes and scopes. It utilizes AI, predictive models, and advanced bioanalytics to develop precision drugs across multiple pharmaceutical and biotechnology categories. Notable competitors include Bristol Myers Squibb.
October 17, 2024
In a significant stride for collaborative drug development, Exscientia plc headquartered in , England and publicly traded on Nasdaq as EXAI has announced the progression of two drug development programs in partnership with Sanofi. These advancements mark crucial milestones in the ongoing collaboration between the two companies, underscoring the potential of AI-driven drug discovery.Exscientia will receive a milestone payment of $15 million, signifying the importance of these developments. This reflects a successful alignment with the predefined product profiles, which both Exscientia and Sanofi collaborated on. These profiles are essential guidelines that help direct the development process and ensure that t...
October 9, 2024
Summary Exscientia plc, a leader in artificial intelligence-driven drug discovery, is poised to present significant new preclinical findings concerning its LSD1 and MALT1 inhibitors at the upcoming 36th EORTC-NCI-AACR (ENA) Symposium 2024, scheduled for October 23-25 in Barcelona, Spain. These developments mark a significant step forward in Exscientia s commitment to advancing innovative therapies for oncology, a field in which precision medicine has become critically important.The ongoing evolution of drug discovery technologies has invigorated the pharmaceutical industry, particularly in the domain of precision medicine. Exscientia is at the forefront of this innovation, employing artificial intelligence (...
July 18, 2024
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data ReadoutOXFORD, England - Exscientia, a leading artificial intelligence (AI) driven biopharmaceutical company, has recently announced its acquisition of GT Apeiron s share of the oral CDK7 inhibitor programme. This strategic move grants Exscientia complete control over GTAEXS617 (617), a promising compound with potential best-in-class features. The acquisition also includes all related intellectual property, further strengthening Exscientia s drug discovery portfolio.The CDK7 (Cyclin-Dependent Kinase 7) enzyme plays a crucial role in regulating cell division and transcription. Inhibiting CDK7 has em...
Absci Corp's business model focuses on driving innovation in drug discovery and development through their integrated synthetic biology platform. They offer a comprehensive suite of services that enable clients to rapidly and efficiently discover, develop, and manufacture new biotherapeutics.
Schrodinger Inc is a computational drug discovery company that utilizes physics-based solutions to accelerate the discovery and development of new drugs. Their business model involves providing software and services to pharmaceutical and biotechnology companies, enabling them to optimize and streamline their drug discovery processes. By leveraging their unique expertise in computational chemistry and molecular modeling, Schrodinger aims to empower their clients in the pursuit of efficient and effective drug development.
Sources:
Exscientia Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Exscientia Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
